This is the authors' abstract. We don't add key points for this paper.
We demonstrated a rapid reduction of FcεRI receptor density on basophils following treatment with omalizumab. Because CU-BAT using well-characterized, omalizumab-naïve donor basophils did not change during the treatment phase, autoreactive serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab on basophils. To predict the omalizumab response time and to monitor disease, FcεRI density and CU-BAT might be promising cellular-based assays.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jörg et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: